CTI-1601
Phase 2Biologic
CTI-1601 is one of 8 biologic programs targeting Friedreich ataxia. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Friedreich Ataxia
#DrugCompanyPhaseTrials
1Skyclarys
BiogenApproved
Actos
TakedaApproved
Ferriprox
Chiesi Farmaceutici S.p.A.Approved
Chantix
PPrism Pharmaceuticals
Approved
Vatiquinone
PPTC Therapeutics
Phase 3
Nomlabofusp
LLarimar Therapeutics, Inc.
Phase 3
Avicel
SSanthera Pharmaceuticals
Preclinical
CTI-1601
LLarimar Therapeutics, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ataxia3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTI-1601. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- LLarimar Therapeutics, Inc.